Metabolische Konsequenzen der Peritonealdialyse

Zusammenfassung

Zur Behandlung der terminalen Niereninsuffizienz kann alternativ zur Hämodialyse auch die Peritonealdialyse eingesetzt werden. Hierbei wird die Bauchhöhle mit 2 – 3 l Dialyseflüssigkeit gefüllt, die in regelmäßigen Abständen gewechselt wird. Um einen osmotischen Gradienten aufzubauen und dem Körper Flüssigkeit entziehen zu können, wird der Dialyseflüssigkeit Glukose zugesetzt. Ein Teil dieser Glukose wird während der Behandlung resorbiert und beeinflusst den Kohlenhydratstoffwechsel des Patienten. Dies ist vor allem bei Diabetikern bedeutsam, die aber bei geeigneter Steuerung durchaus mit Peritonealdialyse behandelt werden können.

Patienten weisen unterschiedliche Glukosetransportcharakteristika auf. Die jeweilige Dialyseverordnung muss die Transportcharakteristik berücksichtigen und hat Einfluss auf die Glukoseresorption. Zur Verringerung der Glukoseaufnahme kann auch die Polyglukose Icodextrin als osmotisches Agens eingesetzt werden. Es gibt Hinweise, dass dies zu einer besseren Stoffwechselführung bei Diabetikern beitragen kann. Allerdings sind diagnostische Besonderheiten zu beachten, da Icodextrin das Glukosemonitoring des Diabetikers beeinflussen kann.

Abstract

Peritoneal dialysis is a feasible alternative for hemodialysis in the treatment of end-stage renal failure. Treatment is done by filling the peritoneum with 2 – 3 l of dialysis fluid which is exchanged several times a day. Dialysis fluid is enriched with glucose to build up an osmotic gradient. This is needed to remove fluid from the patient. Glucose which can be resorbed from the peritoneum influences the carbohydrate metabolism of the patient. Although this is particularly relevant to the patient with diabetes, this comorbidity is not a contraindication to peritoneal dialysis.

Patients have different peritoneal transport characteristics leading to different amounts of glucose being resorbed in a defined time. This transport characteristic has to be considered when designing a peritoneal dialysis prescription. The polyglucose Icodextrin can be used to reduce the glucose load to the patient. It has similar osmotic effects while hardly being resorbed. The literature gives hints that the use of Icodextrin improves metabolic adjustment in patients with diabetes. Some diagnostic aspects have to be considered when treating patients with diabetes by Icodextrin since the substance can influence glucose monitoring.

Schlüsselwörter

Peritonealdialyse - Niereninsuffizienz - Glukosemonitoring

Keywords

peritoneal dialysis - chronic kidney failure - glucose monitoring

• Literatur

• 1 Yeates K, Zhu N, Vonesh E. et al. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. Nephrol Dial Transplant 2012; 27: 3568-3575
• 2 Vonesh EF, Snyder JJ, Foley RN. et al. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004; 66: 2389-2401
• 3 Dong R, Guo ZY. Gastrointestinal symptoms in patients undergoing peritoneal dialysis: multivariate analysis of correlated factors. World J Gastroenterol 2010; 16: 2812-2817
• 4 Lee YC, Hung SY, Wang HH. et al. Different Risk of Common Gastrointestinal Disease Between Groups Undergoing Hemodialysis or Peritoneal Dialysis or With Non-End Stage Renal Disease: A Nationwide Population-Based Cohort Study. Medicine (Baltimore) 2015; 94: e1482
• 5 Tziviskou E, Musso C, Bellizzi V. et al. Prevalence and pathogenesis of hypokalemia in patients on chronic peritoneal dialysis: one center's experience and review of the literature. Int Urol Nephrol 2003; 35: 429-434
• 6 Ribeiro SC, Figueiredo AE, Barretti P. et al. Low Serum Potassium Levels Increase the Infectious-Caused Mortality in Peritoneal Dialysis Patients: A Propensity-Matched Score Study. PLoS One 2015; 10: e0127453
• 7 Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 1984; 27: 351-357
• 8 Joy MS, Cefalu WT, Hogan SL. et al. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002; 39: 297-307
• 9 Twardowski ZJ, Nolph KD, Khanna R. et al. Daily clearances with continuous ambulatory peritoneal dialysis and nightly peritoneal dialysis. ASAIO Trans 1986; 32: 575-580
• 10 Burkart J. Metabolic consequences of peritoneal dialysis. Semin Dial 2004; 17: 498-504
• 11 Choi SJ, Park MY, Kim JK. et al. The 24-month changes in body fat mass and adipokines in patients starting peritoneal dialysis. Perit Dial Int 2017; [Epub ahead of print]
• 12 Rincon Bello A, Bucalo L, Abad Estebanez S. et al. Fat tissue and inflammation in patients undergoing peritoneal dialysis. Clin Kidney J 2016; 9: 374-380
• 13 Paniagua R, Ventura MD, Avila-Diaz M. et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int 2009; 29: 422-432
• 14 Fiedler R, Dorligjav O, Seibert E. et al. Vitamin D Deficiency, Mortality, and Hospitalization in Hemodialysis Patients with or without Protein-Energy Wasting. Nephron Clin Pract 2011; 119: c220-c226
• 15 Perl J, Huckvale K, Chellar M. et al. Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1201-1206
• 16 Tjiong HL, Swart R, van den Berg JW. et al. Amino Acid-based peritoneal dialysis solutions for malnutrition: new perspectives. Perit Dial Int 2009; 29: 384-393
• 17 Holzer M, Schilcher G, Curcic S. et al. Dialysis Modalities and HDL Composition and Function. J Am Soc Nephrol 2015; 26: 2267-2276
• 18 Hiramatsu T, Furuta S, Kakuta H. Favorable changes in lipid metabolism and cardiovascular parameters after icodextrin use in peritoneal dialysis patients. Adv Perit Dial 2007; 23: 58-61
• 19 Li PK, Culleton BF, Ariza A. et al. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol 2013; 24: 1889-1900